醫師學術論文
Paper鄭文建 Wen-Chien Cheng 主治醫師
鄭文建醫師為本校畢業生,為內科醫學,胸腔曁重症醫學,肺癌醫學及高壓氧醫學專科醫師。專注於肺癌,肺纖維化,及呼吸道疾病 (氣喘,慢性肺阻塞) 的診治,且對待病人親切。熱衷於基礎及臨床結合研究,目前在中興大學生科院轉譯學程攻讀博士班。
學術機構典藏
論文
期刊論文
期刊論文/Journal Paper (作者群,論文題目,期刊名稱,出版年月,卷號(期別):頁次起迄) |
日期 | |
1 | 陳昫元(CHEN HSU-YUAN)、陳家弘(Chia-Hung Chen)、廖偉志(Liao, Wei-Chih)、林裕超(Yu-Chao Lin)、陳鴻仁(Hung-Jen Chen)、夏德椿(Te-Chun Hsia)、鄭文建(Wen-Chien Cheng)*、涂智彥(Chih-Yen Tu)*,Optimal First-Line Treatment for EGFR-Mutated NSCLC: A Comparative Analysis of Osimertinib and Second-Generation EGFR-TKIs,BMC Pulmonary Medicine,2024 Oct,2024(24):517 | 2024 . 10 |
2 | 陳鴻仁(Hung-Jen Chen)、鄭文建(Wen-Chien Cheng)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、梁基安(Ji-An Liang)、李佳瑾、簡君儒(Chien, Chun-Ru)*,Efficacy of Respiration-controlled Radiotherapy Among Patients With Locally Advanced-stage Lung Cancer: A Population-based Study,ANTICANCER RESEARCH,2024 Sep,44(9):4093-4100 | 2024 . 09 |
3 | 陳鴻仁(Hung-Jen Chen)、鄭文建(Wen-Chien Cheng)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、林昱森(Yu-Sen Lin)、方信元(Hsin-Yuan Fang)、李佳瑾、簡君儒(Chien, Chun-Ru)*,Stereotactic ablative radiotherapy versus conventional fractionated radiotherapy for clinical early-stage non-small-cell lung cancer: a population-based study,Thoracic Cancer,2024 Aug,24():1779-1791 | 2024 . 08 |
4 | 黃維俊(Wei-Chun Huang)、鄭文建(Wen-Chien Cheng)*、陳致宇(Chih-Yu Chen)、廖偉志(Liao, Wei-Chih)、吳秉儒(Bing-Ru Wu)、陳偉峻(Wei-Chun chen)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)*、徐武輝(Wu-Huei Hsu),Comparison of Budesonide/Formoterol versus Fluticasone Furoate/Vilanterol as Maintenance and Reliever Therapy for Asthma Control: A Real-World Observational Study,BMC Pulmonary Medicine,2024 Aug,1(24):474 | 2024 . 08 |
5 | 鄭文建(Wen-Chien Cheng)、陳沛瀠(Pei Ying Chen)、(Xiang Zhang)、(Yu-Kang Chang)、(Kok-Tong Tan)*、林季千(Chi-Chien Lin)*,5,7,3',4'-Tetramethoxyflavone suppresses TGF-β1-induced activation of murine fibroblasts in vitro and ameliorates bleomycin-induced pulmonary fibrosis in mice,IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY,2024 Jun,(Jul 1):1-13 | 2024 . 06 |
6 | 鄭文建(Wen-Chien Cheng)*、張嘉凌(Chia-Ling Chang)、許超群(Chau-Chyun Sheu)、王秉槐(Ping-Huai Wang)、謝孟亨(Meng-heng Hsieh)、陳明琮(Ming-Tsung Chen)、歐偉凡(Wei-Fan Ou)、魏裕峰(Yu-Feng Wei)、楊聰明(Tsung-Ming Yang)、藍冑進(Chou-Chin Lan)、王誠一(Cheng-Yi Wang)、林智斌(Chih-Bin Lin,)、林明憲(Ming-Shian Lin)、王耀東(Yao-Tung Wang)、林慶雄(Ching-Hsiung Lin)、劉世豐(Shih-Feng Liu)、鄭孟軒(Meng-Hsuan Cheng)、陳彥甫(Yen-Fu Chen)、彭忠衎(Chung-Kan Peng)、詹明澄(Ming-Cheng Chan)、陳靜宜(Ching-Yi Chen)、饒倫毓(Lun-Yu Jao)、王雅蕙(Ya-Hui Wang)、陳頎叡(Chi-Jui Chen)、陳世彬(Shih-Pin Chen)、蔡怡萱(Yi-Hsuan Tsai)、鄭世隆(Shih-Lung Cheng)、林鴻銓(Horng-Chyuan Lin)、簡榮彥(Jung-Yien Chien)、王鶴健(Hao-Chien Wang)*、徐武輝(Wu-Huei Hsu)*,Correlating Reif scores with clinical, functional, and prognostic factors: characterizing noncystic fbrosis bronchiectasis severity: validation from a nationwide multicenter study in Taiwan,EUROPEAN JOURNAL OF MEDICAL RESEARCH,2024 May,14(29):286 | 2024 . 05 |
7 | 陳偉峻(Wei-Chun chen)、鄭文建(Wen-Chien Cheng)*、陳傑龍(Chen Chieh-Lung)、廖偉志(Liao, Wei-Chih)、陳家弘(Chia-Hung Chen)、陳鴻仁(Hung-Jen Chen)、涂智彥(Chih-Yen Tu)、林季千(Chi-Chien Lin)*、夏德椿(Te-Chun Hsia),Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy,Cancer Medicine,2024 Apr,13(7): | 2024 . 04 |
8 | 鄭文建(Wen-Chien Cheng)、(Chi-Chien Lin)*、廖偉志(Liao, Wei-Chih)、林裕超(Yu-Chao Lin)、陳家弘(Chia-Hung Chen)、陳鴻仁(Hung-Jen Chen)、涂智彥(Chih-Yen Tu)*、夏德椿(Te-Chun Hsia)*,The diference between dacomitinib and afatinib in efectiveness and safety in frst-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study,BMC CANCER,2024 Feb,24(228): | 2024 . 02 |
9 | 盧緹婕(Ti-Chieh Lu)、沈德群(Shen, Te-Chun)、李修銘(LEE HSIU-MING)、劉得誼(LIU DE-YI)、鄭文建(Wen-Chien Cheng)、顏至慶(Chih-Ching Yen)、吳樺姍(Hua-Shan Wu)*,計步器結合網際網路對肺阻塞病人之成效:隨機對照試驗之統合分析,內科學誌,2024 Feb,35(1):1-13 | 2024 . 02 |
10 | 陳傑龍(Chen Chieh-Lung)、王幸婷(SING TING, WANG)、廖偉志(Wei-Chih Liao)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、夏德椿(Te-Chun Hsia)、鄭文建(Wen-Chien Cheng)*、陳鴻仁(Hung-Jen Chen)*,A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma,BMC CANCER,2023 Sep,23(): | 2023 . 09 |
11 | 鄭文建(Wen-Chien Cheng)、張詩欣(Shih-Hsin Chang)*、陳偉峻(Wei-Chun chen)、吳秉儒(Bing-Ru Wu)、陳家弘(Chia-Hung Chen)、林季千(Chi-Chien Lin)、徐武輝(Wu-Huei Hsu)、藍忠亮(Joung-Liang Lan)、陳得源(Der-Yuan Chen)*,Application of impulse oscillometry to detect interstitial lung disease and airway disease in adults with rheumatoid arthritis,BMC Pulmonary Medicine,2023 Sep,23(2023):331 | 2023 . 09 |
12 | 賴志政(Chih-Cheng Lai)、陳威志(Wei-Chih Chen)、郭立國(Li-Kuo Kuo)、王耀東(Yao-Tung Wang)、傅彬貴(Pin-Kuei Fu)、古世基(Shih-Chi Ku)、方文豐(Wen-Feng Fang)、陳欽明(Chin-Ming Chen)、涂智彥(Chih-Yen Tu)、鄭文建(Wen-Chien Cheng)*、陳家弘(Chia-Hung Chen),The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia,MEDICINE,2023 Jul,102(28): | 2023 . 07 |
13 | 鄭文建(Wen-Chien Cheng)、沈宜成(Yi-Cheng Shen)、陳傑龍(Chen Chieh-Lung)、廖偉志(Wei-Chih Liao)、陳鴻仁(Hung-Jen Chen)、夏德椿(Te-Chun Hsia)、陳家弘(Chia-Hung Chen)*、涂智彥(Chih-Yen Tu)*,The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer,Diagnostics,2023 Jan,13(1):129 | 2023 . 01 |
14 | 陳傑龍(Chen Chieh-Lung)、王幸婷(SING TING, WANG)、鄭文建(Wen-Chien Cheng)、吳秉儒(Bing-Ru Wu)*、廖偉志(Wei-Chih Liao)*、徐武輝(Wu-Huei Hsu),Outcomes and Prognostic Factors in Critical Patients with Hematologic Malignancies,Journal of Clinical Medicine,2023 Jan,2023(12):958-958 | 2023 . 01 |
15 | 鄭文建(Wen-Chien Cheng)、沈宜成(Yi-Cheng Shen)、陳傑龍(Chen Chieh-Lung)、廖偉志(Wei-Chih Liao)、陳家弘(Chia-Hung Chen)、陳鴻仁(Hung-Jen Chen)、涂智彥(Chih-Yen Tu)*、夏德椿(Te-Chun Hsia)*,Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study,Cancers,2023 Jan,15(3):642 | 2023 . 01 |
16 | 黃維俊(Wei-Chun Huang)、陳致宇(Chih-Yu Chen)、廖偉志(Wei-Chih Liao)、吳秉儒(Bing-Ru Wu)、陳偉峻(Wei-Chun chen)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)*、鄭文建(Wen-Chien Cheng)*,Differences in pulmonary function improvement after once-daily LABA/LAMA fixed-dose combinations in patients with COPD,Journal of Clinical Medicine,2022 Dec,11(23): | 2022 . 12 |
17 | 陳國鈺(CHEN GUO-YU)、鄭文建(Wen-Chien Cheng)*、涂智彥(Chih-Yen Tu),Ischemic stroke in a patient with EGFR-mutated non-small-cell lung cancer after treatment with ramucirumab,Thoracic Cancer,2022 Dec,13(): | 2022 . 12 |
18 | 陳昫元(CHEN HSU-YUAN)、郭育筑(KUO YU-CHU)、鄭文建(Wen-Chien Cheng)*、陳韋成(Wei-Cheng Chen),A rare presentation of anaplastic large cell lymphoma as a cavitary pulmonary mass with hypercalcemia,Thoracic Cancer,2022 Jul,(): | 2022 . 07 |
19 | 鄭文建(Wen-Chien Cheng)、(Ya Wen)、(Yen-Shuo Chiu)、周家豪(Chia-Hao Chou)、(Chen-Jen Lim)、(Sheng-Hao Lin)、(Jia-Ming Chang)、林季千(Chi-Chien Lin)*,Pendulone induces apoptosis via the ROS-mediated ER-stress pathway in human non-small cell lung cancer cells,TOXICOLOGY IN VITRO,2022 Jun,12(81): | 2022 . 06 |
20 | 蘇浤傑(SU HUNG-CHIEH)、廖哲琦(LIAO CHE-CHI)、陳傑龍(Chen Chieh-Lung)、廖偉志(Wei-Chih Liao)、鄭文建(Wen-Chien Cheng)*,Concurrent aspergillosis and cystic pulmonary metastases in a patient with tongue squamous cell carcinoma,Open Medicine,2022 Jun,17(1):1325-1329 | 2022 . 06 |
21 | 陳傑龍(Chen Chieh-Lung)、王幸婷(SING TING, WANG)、廖偉志(Wei-Chih Liao)、陳家弘(Chia-Hung Chen)、涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)、夏德椿(Te-Chun Hsia)*、鄭文建(Wen-Chien Cheng)*,When to Add Anti-Angiogenesis Drugs to EGFR-Mutated Metastatic Non–Small Cell Lung Cancer Patients: A Real-World Study from Taiwan,BMC CANCER,2022 May,22():571 | 2022 . 05 |
22 | 鄧紀剛(Teng Chikang)、陳傑龍(Chen Chieh-Lung)、陳鼎翰(Ding-Han Chen)、鄭文建(Wen-Chien Cheng)*、涂智彥(Chih-Yen Tu),Bevacizumab plus dacomitinib combination therapy for L858R-mutated metastatic lung adenocarcinoma: A report of two cases,Thoracic Cancer,2022 May,13(9):1427-1030 | 2022 . 05 |
23 | 鄭文建(Wen-Chien Cheng)、沈宜成(Yi-Cheng Shen)、簡君儒(Chien, Chun-Ru)、廖偉志(Wei-Chih Liao)、陳家弘(Chia-Hung Chen)、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)*,The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from Taiwan,Thoracic Cancer,2022 Mar,2022(): | 2022 . 03 |
24 | (I-Ta Lu)、(Shih-Chao Lin)、(Yi-Chia Chu)、(, Ya Wen)、(You-Cheng Lin)、鄭文建(Wen-Chien Cheng)、(Jyh-Horng Sheu)、林季千(Chi-Chien Lin)*,(−)-Agelasidine A Induces Endoplasmic Reticulum Stress-Dependent Apoptosis in Human Hepatocellular Carcinoma,Marine Drugs,2022 Jan,20(2):109 | 2022 . 01 |
25 | 黃維俊(Wei-Chun Huang)、陳致宇(Chih-Yu Chen)、廖偉志(Wei-Chih Liao)、吳秉儒(Bing-Ru Wu)、陳偉峻(Wei-Chun chen)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)*、鄭文建(Wen-Chien Cheng)*,A Real World Study to Assess the Effectiveness of Switching to Once Daily Closed Triple Therapy from Mono/Dual Combination or Open Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease,International Journal of Chronic Obstructive Pulmonary Disease,2021 Mar,(16):1555-1568 | 2021 . 03 |
26 | 王幸婷(SING TING, WANG)、陳傑龍(Chen Chieh-Lung)、梁世昕(Shih-Hsin, Liang)、葉士芃(Shih-Peng Yeh)、鄭文建(Wen-Chien Cheng)*,Acute myeloid leukemia with leukemic pleural effusion and high levels of pleural adenosine deaminase: A case report and review of literature,Open Medicine,2021 Mar,2021(16):387-396 | 2021 . 03 |
27 | 鄭文建(Wen-Chien Cheng)、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、陳鴻仁(Hung-Jen Chen)*,The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy,OncoTargets and Therapy,2020 Dec,2020(13):13425-13435 | 2020 . 12 |
28 | 鄭文建(Wen-Chien Cheng)、吳秉儒(Bing-Ru Wu)、廖偉志(Wei-Chih Liao)、陳致宇(Chih-Yu Chen)、陳偉峻(Wei-Chun chen)、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)*、徐武輝(Wu-Huei Hsu),When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment,International Journal of Chronic Obstructive Pulmonary Disease,2020 Dec,2020(15):3375-3384 | 2020 . 12 |
29 | 陳鴻仁(Hung-Jen Chen)、陳家弘(Chia-Hung Chen)、陳碩爵(Shuo-Chueh Chen)、林宏霖(Hung-Lin Lin)、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、杭良文(Liang-Wen Hang)、鄭文建(Wen-Chien Cheng)、李佳瑾、簡君儒(Chun-Ru Chien)*,Focal conformal fractionated radiotherapy vs. radiosurgery for lung cancer patients with limited brain metastases,Annals of Palliative Medicine,2020 Sep,9(5):2600-2605 | 2020 . 09 |
30 | 鄧紀剛(Teng Chikang)、鄭文建(Wen-Chien Cheng)*、陳傑龍(Chen Chieh-Lung)、陳鼎翰(Ding-Han Chen)、林昀姍(Lin Yun-Shan)、涂智彥(Chih-Yen Tu),Endobronchial metastases from a primary embryonal carcinoma,Respirology Case Reports,2020 Aug,8(7): | 2020 . 08 |
31 | 鄭文建(Wen-Chien Cheng)、沈孟芳(Meng-Fang Shen)、吳秉儒(Bing-Ru Wu)、廖偉志(Wei-Chih Liao)、陳致宇(Chih-Yu Chen)、陳偉峻(Wei-Chun chen)、陳家弘(Chia-Hung Chen)*、涂智彥(Chih-Yen Tu),Identification of Specific Endobronchial Ultrasound Features to Differentiate Sarcoidosis From Other Causes of Lymphadenopathy,JOURNAL OF ULTRASOUND IN MEDICINE,2020 Jun,2020(9999):1-10 | 2020 . 06 |
32 | 陳傑龍(Chen Chieh-Lung)、黃維俊(Wei-Chun Huang)、鄭文建(Wen-Chien Cheng)*,Catamenial hemoptysis,QJM-AN INTERNATIONAL JOURNAL OF MEDICINE,2020 May,113(): | 2020 . 05 |
33 | 陳致宇(Chih-Yu Chen)、吳秉儒(Bing-Ru Wu)、陳家弘(Chia-Hung Chen)、鄭文建(Wen-Chien Cheng)、陳偉峻(Wei-Chun chen)、廖偉志(Wei-Chih Liao)*、陳志毅、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu),Prognostic Value of Tumor Size in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer,Journal of Clinical Medicine,2020 May,9(): | 2020 . 05 |
34 | 鄭文建(Wen-Chien Cheng)、沈孟芳(Meng-Fang Shen)、吳秉儒(Bing-Ru Wu)、陳致宇(Chih-Yu Chen)、陳偉峻(Wei-Chun chen)、廖偉志(Wei-Chih Liao)、陳家弘(Chia-Hung Chen)*、涂智彥(Chih-Yen Tu)*,The prognostic predictors of patients with airway involvement due to advanced esophageal cancer after metallic airway stenting using flexible bronchoscopy,Journal of Thoracic Disease,2019 Sep,11(9):3929-3940 | 2019 . 09 |
35 | 鄭文建(Wen-Chien Cheng)、廖偉志(Wei-Chih Liao)、吳秉儒(Bing-Ru Wu)、陳致宇(Chih-Yu Chen)、沈孟芳(Meng-Fang Shen)、陳偉峻(Wei-Chun chen)、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)*、徐武輝(Wu-Huei Hsu),Clinical predictors of asthmatics in identifying subgroup requiring long-term tiotropium add-on therapy: a real-world study,Journal of Thoracic Disease,2019 Sep,11(9):3785-3793 | 2019 . 09 |
36 | 鄭文建(Wen-Chien Cheng)、陳家弘(Chia-Hung Chen)*,Editorial:Nanotechnology bring a new hope for asthmatics,Annals of Translational Medicine,2019 Sep,7(20):516 | 2019 . 09 |
37 | 廖偉志(Wei-Chih Liao)、鄭文建(Wen-Chien Cheng)、吳秉儒(Bing-Ru Wu)、陳偉峻(Wei-Chun chen)、陳致宇(Chih-Yu Chen)、陳家弘(Chia-Hung Chen)*、涂智彥(Chih-Yen Tu)*、夏德椿(Te-Chun Hsia),Outcome and prognostic factors of patients treated in the intensive care unit for carbon monoxide poisoning,JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION,2018 Oct,117(): | 2018 . 10 |
38 | 鄭文建(Wen-Chien Cheng)、吳秉儒(Bing-Ru Wu)、廖偉志(Wei-Chih Liao)、陳致宇(Chih-Yu Chen)、陳偉峻(Wei-Chun chen)、夏德椿(Te-Chun Hsia)、涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)*、徐武輝(Wu-Huei Hsu),Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: a real-life study,Journal of Thoracic Disease,2018 Jun,10(6):3661-3669 | 2018 . 06 |
39 | 鄭文建(Wen-Chien Cheng)、吳秉儒(Biing-Ru Wu)、陳家弘(Chen, Chia-Hung)、廖偉志(Liao, Wei-Chih)、涂智彥(Tu, Chih-Yen)*,Medical thoracoscopy removal of a self-expandable metallic stent migration into pleural cavity,Journal of Thoracic Disease,2018 May,10(5):3054-3058 | 2018 . 05 |
40 | 涂智彥(Tu, Chih-Yen)、陳全木(Chuan-Mu Chen)、廖偉志(Liao, Wei-Chih)*、吳秉儒(Biing-Ru Wu)、陳致宇(Chih-Yu Chen)、陳偉峻(Chen, Wei-Chun)、夏德椿(Hsia, Te-Chun)、鄭文建(Wen-Chien Cheng)、陳家弘(Chen, Chia-Hung)*,Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations,Oncotarget,2018 Feb,():1-8 | 2018 . 02 |
41 | 陳家弘(Chen, Chia-Hung)、鄭文建(Wen-Chien Cheng)、吳秉儒(Biing-Ru Wu)、陳致宇(Chih-Yu Chen)、陳偉峻(Chen, Wei-Chun)、廖偉志(Liao, Wei-Chih)、涂智彥(Tu, Chih-Yen)*,Feasibility and Safety of Pleuroscopic Cryobiopsy of the Pleura: A Prospective Study,Canadian Respiratory Journal,2018 Jan,2018(1):1-8 | 2018 . 01 |
42 | 陳家弘(Chia-Hung Chen)、吳秉儒(Biing-Ru Wu)、鄭文建(Wen-Chien Cheng)、陳致宇(Chih-Yu Chen)、陳偉峻(Wei-Chun chen)、夏德椿(Te-Chun Hsia)、廖偉志(Wei-Chih Liao)、涂智彥(Chih-Yen Tu)*、徐武輝(Wu-Huei Hsu),Interventional pulmonology for patients with central airway obstruction: An 8-year institutional experience,MEDICINE,2017 Jan,(): | 2017 . 01 |
43 | 陳偉峻(Wei-Chun chen)、陳韋成(Chen Wei-cheng)、陳致宇(Chih-Yu Chen)、吳秉儒(Biing-Ru Wu)、鄭文建(Wen-Chien Cheng)、林?宏(Kuo-Hung Lin)、夏德椿(Te-Chun Hsia)、陳煒(Wei Chen)、陳家弘(Chia-Hung Chen)、莫之欣、李嘉翔(Chia-Hsiang Li)*、廖偉志(Wei-Chih Liao)*,Amiodarone Use Is Associated With Increased Risk of Stroke in Patients With Nonvalvular Atrial Fibrillation A Nationwide Population-Based Cohort Study,MEDICINE,2015 May,19(6): | 2015 . 05 |
44 | 鄭文建(Wen-Chien Cheng)、沈德群(Te-Chun Shen)*、涂智彥(Chih-Yen Tu),Achalasia and the Rat's Tail Sign,QJM-AN INTERNATIONAL JOURNAL OF MEDICINE,2014 Jul,107(7):583-583 | 2014 . 07 |
45 | 鄭文建(Wen-Chien Cheng)、夏德椿(Te-Chun Hsia)、廖偉志(Wei-Chih Liao)、陳家弘(Chia-Hung Chen)、陳偉峻(Wei-Chun chen)*,Systemic intravascular and extravascular air bubbles in type I decompression sickness,EMERGENCY MEDICINE JOURNAL,2014 Mar,0(1):0-0 | 2014 . 03 |
研討會論文
研討會論文/Conference Papers (發表主題或論文名稱,研討會名稱,演講地點,研討會期間,受邀演講題目) |
日期 | |
1 | 揭密吉舒達的隱憂:甲狀腺低下誘發橫紋肌溶解的肺癌個案呈現,台灣內科醫學會113年會員大會暨學術演講會,臺大醫院國際會議中心,2024.11.30~2024.12.01, | 2024 . 11 |
2 | 以胃麻痺為表現的免疫相關不良事件:一位66歲小細胞肺癌患者接受Durvalumab的治療案例,台灣內科醫學會112年會員大會暨學術演講會,臺大醫院國際會議中心,2023.12.02~2023.12.03, | 2023 . 12 |
3 | 第三期肺腺癌接受同步放射化學治療後引起之乳糜胸,台灣內科醫學會112年會員大會暨學術演講會,台大國際會議中心,2023.12.02~2023.12.03, | 2023 . 12 |
4 | 第二代EGFR TKI與Osimertinib 在晚期表皮生長因子突變的非小細胞肺癌病人治療的比較:一項真實世界之觀察性研究,2023 台灣胸腔暨重症加護醫學會年會,台大醫院國際會議中心,2023.12.09~2023.12.10, | 2023 . 12 |
5 | 一位肝細胞癌男性患者經動脈化學栓塞術後併發支氣管膽道廔管:案例報告,台灣內科醫學會112年「會員大會暨學術演講會」,臺大醫院國際會議中心,2023.12.02~2023.12.03, | 2023 . 12 |
6 | 應用圓徑探頭氣管內視鏡超音波(EBUS)於呼吸衰竭病人在加護病房之效用和安全性:一家醫學中心的經驗,2023台灣胸腔暨重症加護醫學會年會暨第19屆第1次會員大會暨台灣胸腔外科醫學會、台灣胸腔及心臟血管外科學會聯合會議,台大國際會議中心 (台北市中正區徐州路2號),2023.12.09~2023.12.10, | 2023 . 12 |
7 | Impact of smoking on the outcome of Immune Checkpoint Inhibitor Treatment in High PD-L1 Expression Non-squamous Non-small-cell Lung Cancer Patients: A Real-World Observational Study,2023台灣胸腔暨重症加護醫學會年會,台大國際會議中心,2023.12.09~2023.12.10, | 2023 . 12 |
8 | The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia,European Respiratory Society (ERS) International Congress 2023,米蘭MiCO,2023.09.09~2023.09.13, | 2023 . 09 |
9 | The clinical feature and optimal treatment strategy of bone metastasis in EGFR mutated NSCLC patients,European Respiratory Society (ERS) International Congress 2023,米蘭,2023.09.09~2023.09.13, | 2023 . 09 |
10 | Afatinib vs Dacomitinib as first line treatment in advanced EGFR mutated NSCLC patients : An observational study,2023 Lung Cancer Summer Summit,台北寒舍艾美酒店,2023.07.08~2023.07.09, | 2023 . 07 |
11 | Dacomitinib一線使用於EGFR突變晚期非小細胞肺癌患者的實際臨床經驗,2022台灣胸腔暨重症加護醫學會年會暨第18屆第3次會員大會,高雄萬豪酒店8F,2022.12.10~2022.12.11, | 2022 . 12 |
12 | 肺部鱗狀細胞癌,接受 Nivolumab 後併發乾癬,台灣內科醫學會111年會員大會暨學術演講會,台大醫院國際會議中心,2022.12.3 ~2022.12.4 , | 2022 . 12 |
13 | Using business intelligence real-time visualization system for improving outcomes in chronic obstructive pulmonary disease patients.,台灣胸腔暨重症加護醫學會年會,高雄萬豪酒店8F,2022.12.10~2022.12.11, | 2022 . 12 |
14 | 一位非小細胞肺癌合併多處轉移病人在使用血管新生抑制劑ramucirumab後發生新出現的缺血性中風,111年會員大會暨學術演講會,台大醫院國際會議中心,2022.12.3 ~2022.12.4 , | 2022 . 12 |
15 | Endobronchial ultrasound-guided transbronchial mini forceps biopsy (TBMFB)from cytologic to histopathologic specimens,台灣胸腔暨重症加護醫學會年會,高雄萬豪酒店8F,2022.12.10~2022.12.11, | 2022 . 12 |
16 | 嗜伊紅性肉芽腫多發性血管炎併發肺栓塞及肺高壓 : 案例報告,台灣內科醫學會111年「會員大會暨學術演講會」,台大醫院國際會議中心,2022.12.3 ~2022.12.4 , | 2022 . 12 |
17 | Pneumocystis Jirovecii Infection following ARDS due to Mycoplasma Pneumoniae in an Immunocompetent Patient,SECC-Best of SCCM Congress 2021 Taipei暨台灣急重症年會,張榮發基金會國際會議中心,2021.12.18~2021.12.19, | 2021 . 12 |
18 | 抗藥性肺結核和隱球菌合併感染的病例報告,台灣內科醫學會「110 年會員大會暨學術演講會」,台大醫院國際會議中心,2021.12.4 ~2021.12.5 , | 2021 . 12 |
19 | 退行性大細胞淋巴癌罕見以開洞性肺部腫瘤合併高血鈣表現,台灣內科醫學會110年會員大會暨學術演講會,台大醫院國際會議中心,2021.12.4 ~2021.12.5 , | 2021 . 12 |
20 | 一位47歲女性的口香糖樣,台灣內科醫學會110年會員大會暨學術演講會,臺大醫院國際會議中心,2021.12.4 ~2021.12.5 , | 2021 . 12 |
21 | L858R突變的轉移性肺腺癌患者使用dacomitinib加bevacizumab聯合治療-病例報告,2021台灣胸腔暨重症加護醫學會年會暨第18屆第2次會員大會,台中榮民總醫院研究大樓、教學大樓,2021.12.11~2021.12.12, | 2021 . 12 |
22 | 一位47歲月經性氣胸女性之案例報告,「台灣內科醫學會 110 年會員大會暨學術演講會,台大醫院國際會議中心,2021.12.4 ~2021.12.5 , | 2021 . 12 |
23 | 支氣管內視鏡超音波指引無X光透視法經氣管冷凍活檢在肺部疾病診斷的安全性及可行性,台灣胸腔暨重症加護醫學會2020年年會,台大國際會議中心 301室,2020.12.12~2020.12.13, | 2020 . 12 |
24 | 流感嗜血桿菌相關社區型肺炎的結果預測因子和產生β-內醯胺酶的流感嗜血桿菌的臨床意義,台灣胸腔暨重症加護醫學會 2020 年胸腔年會暨第 18 屆第 1 次會員大會,台大醫院國際會議中心,2020.12.12~2020.12.13, | 2020 . 12 |
25 | The high concordance of EGFR mutation status between tissue and needle washed fluid which was obtained from EBUS-TBNA for advanced lung adenocarcinoma,台灣胸腔暨重症加護醫學會 2019 年胸腔年會暨第 17 屆第 3 次會員大會,高雄展覽館,2019.12.07~2019.12.08, | 2019 . 12 |
專書
專書/Books (作者,書名,出版商,出版日期) |
日期 | |
1 | 涂智彥(Chih-Yen Tu)、陳家弘(Chia-Hung Chen)、廖偉志(Wei-Chih Liao)、吳秉儒(Bing-Ru Wu)、鄭文建(Wen-Chien Cheng),內科肋膜腔鏡操作指引,合記圖書出版社,2021.1 | 2021 . 01 |
研究計畫
研究計畫/Research Grant (研究類型,研究計畫代號,主持人,補助或委託單位名稱,計畫名稱,計畫期間) |
日期 | |
1 | 個別型,DMR-113-099,黃柏豪(Po-Hao Huang)、楊凱介(YEO KAI-JIEH)、張詩欣(Shih-Hsin Chang)、鄭文建(Wen-Chien Cheng),本校(含附醫),間貭性肺炎病患血液中循環纖維細胞與疾病活動度、肺纖化程度之關聯,2023.8.1~2024.7.31 | 2023 . 08 |
2 | 個別型,DMR-112-027,林季千(Chi-Chien Lin)、吳秉儒(Bing-Ru Wu),附醫院內計畫,探討Arnicolide D抑制人類小細胞肺癌生長之功效及機制,2022.8.1~2023.7.31 | 2022 . 08 |
3 | 個別型,DMR-112-097,陳家弘(Chia-Hung Chen)、鄭文建(Wen-Chien Cheng)、張倍禎(Jane Pei-Chen Chang)、蘇冠賓(Kuan-Pin Su),附醫院內計畫,Omega -3 多元不飽和脂肪酸在慢性阻塞性肺疾病(COPD)共病憂鬱症之雙盲療效研究,2022.8.1~2023.7.31 | 2022 . 08 |
專利技術
暫無資料獲獎事蹟
獲獎/Award (獲獎名稱,給獎單位,獲獎日期) |
日期 | |
1 | Junior Research Award-年輕醫師研究潛力獎,社團法人台灣胸腔暨重症加護醫學會,2023.12.9 | 2023 . 12 |
2 | 2023 Lung Cancer Summer Summit-學術論文競賽口頭報告-優選,台灣肺癌學會,2023.7.9 | 2023 . 07 |